I-Mab (NASDAQ:NBP) Upgraded at Wall Street Zen

I-Mab (NASDAQ:NBP) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also issued research reports about the stock. HC Wainwright boosted their target price on shares of I-Mab from $7.00 to $9.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings assumed coverage on I-Mab in a research report on Thursday. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $9.00.

I-Mab Price Performance

NASDAQ NBP opened at $3.70 on Friday. I-Mab has a 12 month low of $0.60 and a 12 month high of $6.79.

I-Mab (NASDAQ:NBP) last announced its earnings results on Thursday, December 18th. The company reported ($0.07) EPS for the quarter.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.